Gail D'Onofrio1, Marek C Chawarski2,3, Patrick G O'Connor4, Michael V Pantalon2, Susan H Busch5, Patricia H Owens2, Kathryn Hawk2, Steven L Bernstein2, David A Fiellin4,5. 1. Department of Emergency Medicine, Yale School of Medicine, New Haven, CT, USA. gail.donofrio@yale.edu. 2. Department of Emergency Medicine, Yale School of Medicine, New Haven, CT, USA. 3. Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA. 4. Department of General Medicine, Yale School of Medicine, New Haven, CT, USA. 5. Yale School of Public Health, New Haven, CT, USA.
Abstract
BACKGROUND: Emergency department (ED)-initiated buprenorphine/naloxone with continuation in primary care was found to increase engagement in addiction treatment and reduce illicit opioid use at 30 days compared to referral only or a brief intervention with referral. OBJECTIVE: To evaluate the long-term outcomes at 2, 6 and 12 months following ED interventions. DESIGN: Evaluation of treatment engagement, drug use, and HIV risk among a cohort of patients from a randomized trial who completed at least one long-term follow-up assessment. PARTICIPANTS: A total of 290/329 patients (88% of the randomized sample) were included. The followed cohort did not differ significantly from the randomized sample. INTERVENTIONS: ED-initiated buprenorphine with 10-week continuation in primary care, referral, or brief intervention were provided in the ED at study entry. MAIN MEASURES: Self-reported engagement in formal addiction treatment, days of illicit opioid use, and HIV risk (2, 6, 12 months); urine toxicology (2, 6 months). KEY RESULTS: A greater number of patients in the buprenorphine group were engaged in addiction treatment at 2 months [68/92 (74%), 95% CI 65-83] compared with referral [42/79 (53%), 95% CI 42-64] and brief intervention [39/83 (47%), 95% CI 37-58; p < 0.001]. The differences were not significant at 6 months [51/92 (55%), 95% CI 45-65; 46/70 (66%) 95% CI 54-76; 43/76 (57%) 95% CI 45-67; p = 0.37] or 12 months [42/86 (49%) 95% CI 39-59; 37/73 (51%) 95% CI 39-62; 49/78 (63%) 95% CI 52-73; p = 0.16]. At 2 months, the buprenorphine group reported fewer days of illicit opioid use [1.1 (95% CI 0.6-1.6)] versus referral [1.8 (95% CI 1.2-2.3)] and brief intervention [2.0 (95% CI 1.5-2.6), p = 0.04]. No significant differences in illicit opioid use were observed at 6 or 12 months. There were no significant differences in HIV risk or rates of opioid-negative urine results at any time. CONCLUSIONS: ED-initiated buprenorphine was associated with increased engagement in addiction treatment and reduced illicit opioid use during the 2-month interval when buprenorphine was continued in primary care. Outcomes at 6 and 12 months were comparable across all groups.
RCT Entities:
BACKGROUND: Emergency department (ED)-initiated buprenorphine/naloxone with continuation in primary care was found to increase engagement in addiction treatment and reduce illicit opioid use at 30 days compared to referral only or a brief intervention with referral. OBJECTIVE: To evaluate the long-term outcomes at 2, 6 and 12 months following ED interventions. DESIGN: Evaluation of treatment engagement, drug use, and HIV risk among a cohort of patients from a randomized trial who completed at least one long-term follow-up assessment. PARTICIPANTS: A total of 290/329 patients (88% of the randomized sample) were included. The followed cohort did not differ significantly from the randomized sample. INTERVENTIONS: ED-initiated buprenorphine with 10-week continuation in primary care, referral, or brief intervention were provided in the ED at study entry. MAIN MEASURES: Self-reported engagement in formal addiction treatment, days of illicit opioid use, and HIV risk (2, 6, 12 months); urine toxicology (2, 6 months). KEY RESULTS: A greater number of patients in the buprenorphine group were engaged in addiction treatment at 2 months [68/92 (74%), 95% CI 65-83] compared with referral [42/79 (53%), 95% CI 42-64] and brief intervention [39/83 (47%), 95% CI 37-58; p < 0.001]. The differences were not significant at 6 months [51/92 (55%), 95% CI 45-65; 46/70 (66%) 95% CI 54-76; 43/76 (57%) 95% CI 45-67; p = 0.37] or 12 months [42/86 (49%) 95% CI 39-59; 37/73 (51%) 95% CI 39-62; 49/78 (63%) 95% CI 52-73; p = 0.16]. At 2 months, the buprenorphine group reported fewer days of illicit opioid use [1.1 (95% CI 0.6-1.6)] versus referral [1.8 (95% CI 1.2-2.3)] and brief intervention [2.0 (95% CI 1.5-2.6), p = 0.04]. No significant differences in illicit opioid use were observed at 6 or 12 months. There were no significant differences in HIV risk or rates of opioid-negative urine results at any time. CONCLUSIONS: ED-initiated buprenorphine was associated with increased engagement in addiction treatment and reduced illicit opioid use during the 2-month interval when buprenorphine was continued in primary care. Outcomes at 6 and 12 months were comparable across all groups.
Entities:
Keywords:
emergency medicine; opioid use disorder; primary care; substance use disorder
Authors: David A Fiellin; Michael V Pantalon; Marek C Chawarski; Brent A Moore; Lynn E Sullivan; Patrick G O'Connor; Richard S Schottenfeld Journal: N Engl J Med Date: 2006-07-27 Impact factor: 91.245
Authors: Gail D'Onofrio; Patrick G O'Connor; Michael V Pantalon; Marek C Chawarski; Susan H Busch; Patricia H Owens; Steven L Bernstein; David A Fiellin Journal: JAMA Date: 2015-04-28 Impact factor: 56.272
Authors: Gail D'Onofrio; Michael V Pantalon; Linda C Degutis; David A Fiellin; Susan H Busch; Marek C Chawarski; Patricia H Owens; Patrick G O'Connor Journal: Ann Emerg Med Date: 2008-04-23 Impact factor: 5.721
Authors: Joji Suzuki; Michele L Matthews; David Brick; Minh-Thuy Nguyen; Ajay D Wasan; Robert N Jamison; Andrew L Ellner; Lori W Tishler; Roger D Weiss Journal: J Opioid Manag Date: 2014 May-Jun
Authors: Herbert C Duber; Isabel A Barata; Eric Cioè-Peña; Stephen Y Liang; Eric Ketcham; Wendy Macias-Konstantopoulos; Shawn A Ryan; Mark Stavros; Lauren K Whiteside Journal: Ann Emerg Med Date: 2018-06-05 Impact factor: 5.721
Authors: Wilson M Compton; Christopher M Jones; Grant T Baldwin; Frances M Harding; Carlos Blanco; Eric M Wargo Journal: Am J Public Health Date: 2019-06 Impact factor: 9.308
Authors: Maribeth C Lovegrove; Deborah Dowell; Andrew I Geller; Sandra K Goring; Kathleen O Rose; Nina J Weidle; Daniel S Budnitz Journal: Am J Public Health Date: 2019-03-21 Impact factor: 9.308
Authors: Amber L Bahorik; Derek D Satre; Andrea H Kline-Simon; Constance M Weisner; Kelly C Young-Wolff; Cynthia I Campbell Journal: Subst Abus Date: 2017-09-06 Impact factor: 3.716